Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?

Brennan, Emily T.; Joy, Tisha

doi:10.1016/j.cjca.2017.02.013

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 16 Nonetheless, recent research indicates that SAMS, characterized by myalgia without objective signs of muscle inflammation, is largely reversible, and statin re-challenge is often well-tolerated. 17 Apart from poor adherence, underestimation of cardiovascular risk by both healthcare professionals and patients contributes to the failure to achieve therapeutic targets. 18 To improve therapeutic adherence and outcomes, new cholesterol-lowering drugs with different administration methods have been developed.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Bempedoic Acid in Patients with Hyperlipidemia and Non-Alcoholic Fatty Liver Disease

Nisar,

Sohail,

Fatima

et al. 2024

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Hyperlipidemia and its association with cardiovascular diseases have been significant public health concerns for many decades. Statins have long been the primary therapeutic option for lowering cholesterol levels and reducing cardiovascular mortality. However, a substantial number of patients either do not achieve optimal lipid goals with maximally tolerated statin doses or experience statin intolerance. In recent years, there have been remarkable developments in the field of hyperlipidemia management, leading to the approval of novel hypolipidemic drugs in North America and Europe. This article reviews the clinical development of bempedoic acid, a promising new drug, alone and in combination with ezetimibe, as an alternative approach to managing hyperlipidemia. The Phase I trials established the safety and tolerability of bempedoic acid, paving the way for further investigation in Phase II and Phase III trials. Multiple phase II studies evaluated the lipid-lowering efficacy of bempedoic acid as monotherapy or in combination with other hypolipidemic agents, showing significant improvements in lipid levels and inflammatory markers. The recently approved fixed drug combination of bempedoic acid and ezetimibe presents a viable option for patients who need additional LDL-C lowering alongside dietary modifications and maximally tolerated statin therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety of Bempedoic Acid in Patients with Hyperlipidemia and Non-Alcoholic Fatty Liver Disease

Nisar,

Sohail,

Fatima

et al. 2024

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

show abstract

“…In addition, in general, those with statinassociated muscle symptoms may be continued on statins, including the same one that originally caused their symptoms. 22 It is surprising that only 20% of the SAMS patients had tried a change in their treatment in the study. Earlier studies have shown that rechallenge is usually successful, ranging from 60%, as quoted in the current study, to 90% or more, especially in those with concomitant vitamin D deficiency who underwent replacement therapy before rechallenge.…”

mentioning

confidence: 97%

“…In contrast to the benefits of identifying risk groups for SAMS, there is the possibility that excessive counseling by physicians may lead to overreporting by patients, as even blinded vs. unblinded treatment with statins makes a difference (the nocebo effect). In addition, in general, those with statin‐associated muscle symptoms may be continued on statins, including the same one that originally caused their symptoms . It is surprising that only 20% of the SAMS patients had tried a change in their treatment in the study.…”

mentioning

confidence: 99%